San Diego, CA, United States of America

Xiaolun Wang

This inventor holds 26 USPTO granted patents and 14 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Cancer Therapeutics. Top assignees: Mirati Therapeutics, Inc., Pfizer Corporation, Array Biopharma Inc.. Active years: 2015-2026.

USPTO Granted Patents = 26 

% Patents Active = 80.8

 

 

Average Co-Inventor Count = 11.3

ph-index = 4

Forward Citations = 77(Granted Patents)


Company Filing History:


Years Active: 2015-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
KRas G12D Inhibitors
Pan-KRas Inhibitors
SOS1 Inhibitors
Bicyclic-Fused Heteroaryl Compounds
Substituted Amines
PHD Inhibitors
Heterocyclic Compounds
Azaquinazoline
Tetrahydropyridopyrimidine
Azaindole Derivatives
Cardiac Disease Treatment
Vanin-1 Enzyme
26 patents (USPTO):Explore Patents

Title: The Innovative Journey of Xiaolun Wang

Introduction: Xiaolun Wang, a talented inventor based in San Diego, CA, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Wang's latest patents include cutting-edge technologies in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over two decades, Xiaolun Wang has worked for several renowned tech companies, leading research teams and spearheading projects that have revolutionized the industry.

Collaborations: Wang is known for his collaborative spirit, having partnered with top universities and research institutions to further develop his inventions. His ability to work across disciplines has led to the creation of pioneering solutions.

Conclusion: Xiaolun Wang's passion for innovation and his relentless drive to push the boundaries of technology make him a true trailblazer in the world of inventions. His work continues to inspire and shape the future of the industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…